Sapreme Technologies is a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutic.
Sapreme Technologies has raised $17.3M in total funding. The most recent round was Series A. The last funding was announced in October 2021.
Sapreme Technologies's investors include Aglaia BioMedical Ventures.
Sapreme Technologies is headquartered in Bilthoven, The Netherlands.
Sapreme Technologies is a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutic.
Sapreme Technologies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sapreme Technologies — Funding & Investors." VCBacked, October 7, 2021, https://www.vcbacked.co/company/sapreme-technologies. Accessed August 17, 2026.
VCBacked. (2021). Sapreme Technologies — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/sapreme-technologies
{{cite web |title=Sapreme Technologies — Funding & Investors |url=https://www.vcbacked.co/company/sapreme-technologies |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated